Elisabeth M Terveer
Overview
Explore the profile of Elisabeth M Terveer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
480
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Keller J, Terveer E
Aliment Pharmacol Ther
. 2023 Oct;
58(9):946-947.
PMID: 37831533
No abstract available.
12.
Vendrik K, Chernova V, Kuijper E, Terveer E, van Hilten J, Contarino M
BMJ Open
. 2023 Oct;
13(10):e071766.
PMID: 37798034
Introduction: Experimental studies suggest a role of gut microbiota in the pathophysiology of Parkinson's disease (PD) via the gut-brain axis. The gut microbiota can also influence the metabolism of levodopa,...
13.
Groenewegen B, Terveer E, Joosse A, Barnhoorn M, Zwittink R
J Immunother
. 2023 May;
46(6):216-220.
PMID: 37216289
Immune checkpoint inhibitors (ICIs) have improved the prognosis in multiple cancer types. However, ICIs can induce immune-related adverse events such as immune-mediated enterocolitis (IMC). The gut microbiota may be implicated...
14.
Chernova V, Terveer E, van Prehn J, Kuijper E, Keller J, van der Meulen-de Jong A, et al.
Parkinsonism Relat Disord
. 2023 May;
111:105410.
PMID: 37150070
We report a patient with a 5-year diagnosis of akinetic-rigid Parkinson's disease under treatment with Levodopa-Carbidopa Intestinal Gel therapy through a PEG-J tube due to motor complications, in which, in...
15.
Crobach M, Hornung B, Verduin C, Vos M, Hopman J, Kumar N, et al.
Clin Microbiol Infect
. 2023 Mar;
29(7):891-896.
PMID: 36871826
Objectives: To assess the value of screening for Clostridioides difficile colonization (CDC) at hospital admission in an endemic setting. Methods: A multi-centre study was conducted at four hospitals located across...
16.
Ianiro G, Mullish B, Iqbal T, Terveer E, Dahl Baunwall S, Link A, et al.
Lancet Gastroenterol Hepatol
. 2022 Sep;
7(11):979-980.
PMID: 36116455
No abstract available.
17.
Vendrik K, de Meij T, Bokenkamp A, Ooijevaar R, Groenewegen B, Hendrickx A, et al.
Open Forum Infect Dis
. 2022 Jul;
9(7):ofac324.
PMID: 35899275
Fecal microbiota transplantation (FMT) has been reported to decrease the incidence of recurrent urinary tract infections (UTIs), presumably by restoring microbiome diversity and/or uropathogen competition. We report a 16-year-old female...
18.
Groenewegen B, van Lingen E, Ooijevaar R, Wessels E, Feltkamp M, Boeije-Koppenol E, et al.
PLoS One
. 2022 Mar;
17(3):e0265426.
PMID: 35298520
Background: Faecal microbiota transplantation (FMT) is an efficacious treatment for patients with recurrent Clostridioides difficile infections (rCDI). Stool banks facilitate FMT by providing screened faecal suspensions from highly selected healthy...
19.
Nooij S, Terveer E
Gastroenterology
. 2021 Dec;
162(3):994-995.
PMID: 34863789
No abstract available.
20.
Dahl Baunwall S, Terveer E, Frederik Dahlerup J, Erikstrup C, Arkkila P, Vehreschild M, et al.
Lancet Reg Health Eur
. 2021 Oct;
9:100181.
PMID: 34693388
Background: Faecal microbiota transplantation (FMT) is an emerging treatment modality, but its current clinical use and organisation are unknown. We aimed to describe the clinical use, conduct, and potential for...